Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models

May 20th 2025

Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.

Dr Janjigian on Safety Considerations With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

May 19th 2025

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

The OncFive: Top Oncology Articles for the Week of 5/11

May 17th 2025

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

Dr Janjigian on Future Research Directions for Immunotherapy in Gastric/GEJ/Esophageal Cancer

May 15th 2025

Yelena Y. Janjigian, MD, discusses future research directions with nivolumab-based treatments in gastric, GEJ, and esophageal cancer.

Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

FDA Approves Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

The FDA has approved belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dr Uboha on the Role of Biomarkers for Guiding Esophageal Adenocarcinoma Treatment Selection

May 8th 2025

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC

May 6th 2025

Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.

Targeted Treatments Shift the Paradigm of Advanced BTC

May 5th 2025

During the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, an OncLive Peer Exchange® featured insights from expert investigators in the field of BTC.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

KN026 Plus Chemo Improves PFS in Pretreated HER2+ Gastric/GEJ Cancer

May 1st 2025

KN026 plus chemotherapy significantly improves PFS in second-line and later HER2-positive advanced gastric/GEJ cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Dr Chan on Unmet Needs Addressed by the FDA Approval of Cabozantinib for pNET and epNET

April 30th 2025

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

April 29th 2025

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC

April 28th 2025

Treatment with 6.5 mg/kg of tegavivint was associated with primarily grade 1/2 TRAEs in patients with advanced hepatocellular carcinoma.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.